1. Mandel P., Metais P.. Les acidesnucleiques du plasma sanguin chez l'homme. C R Acad Sci Paris 142:1948;241–243.
2. Schwarzenbach H., Hoon D.S.B., Pantel K.. Cell-free nucleic acids as biomarkers in cancer patients.
Nat Rev Cancer 11:2011;426–437.
3. Yi J., Zhang Y., Zhang Y., Ma Y., Zhang C., Li Q., Liu B., Liu Z., Liu J., Zhang X., Zhuang R., Jin B.. Increased plasma cell-free DNA level during HTNV infection: correlation with disease severity and virus load.
Viruses 6:2014;2723–2734.
4. Garnacho-Montero J., Huici-Moreno M.J., Gutierrez-Pizarraya A., Lopez I., Marquez Vacaro J.A., Macher H., Guerrero J.M., Puppo-Moreno A.. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis.
Crit Care 18:2014;R116
5. Elshimali Y.I., Khaddour H., Sarkissyan M., Wu Y., Vadgama J.V.. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.
Int J Mol Sci 14:2013;18925–18958.
6. Atamaniuk J., Hsiao Y.Y., Mustak M., Bernhard D., Erlacher L., Fodinger M., Tiran B., Stuhlmeier K.M.. Analysing cell-free plasma DNA and SLE disease activity.
Eur J Clin Invest 41:2011;579–583.
7. Tsai N.W., Lin T.K., Chen S.D., Chang W.N., Wang H.C., Yang T.M., Lin Y.J., Jan C.R., Huang C.R., Liou C.W., Lu C.H.. The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke.
Clin Chim Acta 412:2011;476–479.
8. Boyko M., Ohayon S., Goldsmith T., Douvdevani A., Gruenbaum B.F., Melamed I., Knyazer B., Shapira Y., Teichberg V.I., Elir A., Klein M., Zlotnik A.. Cell-free DNAFA marker to predict ischemic brain damage in a rat stroke experimental model.
J Neurosurg Anesthesiol 23:2011;222–228.
9. Cui M., Fan M., Jing R., Wang H., Qin J., Sheng H., Wang Y., Wu X., Zhang L., Zhu J., Ju S.. Cell-free circulating DNA: a new biomarker for the acute coronary syndrome.
Cardiology 124:2013;76–84.
10. Taglauer E.S., Wilkins-Haug L., Bianchi D.W.. Review: cell-free fetal DNA in the maternal circulation as an indication of placental health and disease.
Trophoblast Research 28:2014;S64–S68.
11. Korabecna M., Opatrna S., Wirth J., Rulcova K., Eiselt J., Sefrna F., Horinekb A.. Cell-free plasma DNA during peritoneal dialysis and hemodialysis and in patients with chronic kidney disease.
Ann N Y Acad Sci 1137:2008;296–301.
12. Lo Y.M., Tein M.S., Lau T.K., Haines C.J., Leung T.N., Poon P.M., Wainscoat J.S., Johnson P.J., Chang A.M., Hjelm N.M.. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for non-invasive prenatal diagnosis.
Am J Hum Genet 62:1998;768–775.
13. Tovbin D., Novack V., Wiessman M.P., Elkadir A.A., Zlotnik M., Douvdevani A.. Circulating cell-free DNA in hemodialysis patients predicts mortality.
Nephrol Dial Transplant 27:2012;3929–3935.
14. Atamaniuk J., Kopecky C., Skoupy S., Säemann M.D., Weichhart T.. Apoptotic cell-free DNA promotes inflammation in haemodialysis patients.
Nephrol Dial Transplant 27:2012;902–905.
15. Jaber B.L., Cendoroglo M., Balakrishnan V.S., Perianayagam M.C., King A.J., Pereira B.J.. Apoptosis of leukocytes: basic concepts and implications in uremia.
Kidney Int 78(Suppl):2001;197–205.
16. El Tarhouny S.A., Hadhoud K.M., Ebrahem M.M., Al Azizi N.M.. Assessment of cell-free DNA with microvascular complication of type II diabetes mellitus, using PCR and ELISA.
Nucleosides Nucleotides Nucleic Acids 29:2010;228–236.
17. Levine R.J., Qian C., LeShane E.S., Yu K.F., England L.J., Schisterman E.F., Wataganara T., Romero R., Bianchi D.W.. Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia.
Am J Obstet Gynecol 190:2004;707–712.
18. Jylhävä J., Lehtimäki T., Jula A., Moilanen L., Kesäniemi Y., Nieminen M., Kähönen M., Hurme M.. Circulating cell-free DNA is associated with cardiometabolic risk factors: the Health 2000 Survey.
Atherosclerosis 233:2014;307–309.
19. Jylhävä J., Lehtimäki T., Jula A., Moilanen L., Kesäniemi Y.A., Nieminen M.S., Kähönen M., Hurme M.. Circulating cell-free DNA is associated with cardiometabolic risk factors: the Health 2000 Survey.
Atherosclerosis 233:2014;268–271.
20. McGuire A.L., Urosevic N., Chan D.T., Dogra G., Inglis T.J., Chakera A.. The impact of chronic kidney disease and short-term treatment with rosiglitazone on plasma cell-free DNA levels.
PPAR Res 2014:2014;643189